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S U M M A R Y
Objective: To examine forces that drive vaccination policy to eradicate wild- and vaccine-derived
poliovirus, and to focus on the efﬁcacy of vaccines to support decision-making and further research.
Methods: We searched PubMed and Ovid databases for English-language publications, without date
restrictions. We also collected references from major reviews on polio vaccine immunogenicity or
protection. We conducted a meta-analysis of human immunity to polio infections using multiple non-
linear regression, and built a database from a broad (but not systematic) set of polio vaccine studies (46
studies, >10 000 subjects).
Results: The outcome was an immunological model representative of many different datasets.
Parameters measured immunogenicity to both humoral and mucosal immune compartments for Salk
and Sabin vaccines. The immunity model was more highly correlated with the data than a simpler per-
dose efﬁcacy model.
Conclusions: The model offers new insights for immunization policy. We measured the mucosal
immunogenicity of IPV to a precision that is useful in decision-making for end-game polio immunization
policies.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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The global polio eradication initiative (GPEI) is now in its 26th
year. Vaccination has reduced the incidence of worldwide
poliomyelitis from a reported 35 000 (estimated 350 000) cases
in 1988 to roughly 1000 cases per year today.1 India has not
detected transmission since January 2011 and has been removed
from the list of endemic countries.2 Afghanistan, Nigeria, and
Pakistan have yet to interrupt poliovirus transmission.
Challenges that currently face the polio eradication program3
include: vaccine failure in developing countries; the quality of
supplemental immunization activities (SIAs);2 elimination of
vaccine-derived poliovirus (VDPV) circulation in Nigeria;4 plan-
ning for oral polio vaccine (OPV) cessation in the end-game; and
preventing the emergence of VDPVs.5,6 These issues require* Corresponding author. Tel.: +1 626 628 4258.
E-mail address: mbehrend@intven.com (M.R. Behrend).
1201-9712   2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.09.005understanding of how far the acquisition and transmissibility of
poliovirus needs to be reduced to interrupt circulation.
Poliovirus vaccines have been thoroughly reviewed7,8 and
studied for efﬁcacy,9,10 but there are few examples of quantitative
comparisons across vaccine trials. Hird and Grassly reviewed and
measured the mucosal efﬁcacy of inactivated polio vaccine (IPV)
with a regression model.11 Efﬁcacy was within error bounds that
could be epidemiologically relevant, warranting further analyses
and new trial data. An exceptional review by Duintjer Tebbens
et al.12 summarizes the results of individual studies as they pertain
to a compartment model for poliovirus transmission. The analysis
presented here develops an immunity model that uniﬁes phenom-
ena that are sometimes confounders during interpretation. We
attempt to place bounds on IPV induction of mucosal immunity so
the small effect, if any, may be weighed with more certainty on the
epidemiological impact of vaccination policy options.
The purpose of this review is to enhance understanding of
poliovirus intra-host physiology and vaccine efﬁcacy to better
inform decision-making. To support poliovirus eradication activi-
ties, we addressed questions of how well vaccine tools induce
protective immunity against poliovirus transmission. We devel-
oped two models: a simplistic dose-efﬁcacy model and then anociety for Infectious Diseases. Open access under CC BY-NC-ND license.
Table 1
Exclusion criteriaa
Index Exclusion criteria
1. Exposure to poliovirus outside of study design in more
than 10% of subjects
2. Vaccines with nonstandard antigenic properties
(e.g. Sabin IPV)
3. Unknown sample size
4. Non-human primates or other animal models
5. Aggregate data from multiple serotypes
IPV, inactivated polio vaccine.
a Criteria for exclusion from the vaccine study database.
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to capture more phenomena affecting immunogenicity of polio
vaccines than per-dose efﬁcacy models.
2. Methods
We searched the PubMed and Ovid databases for English-
language publications, without date restrictions, with the search
terms (Sabin OR oral) AND polio AND vaccine, (Salk OR inactivated)
AND polio AND vaccine, and polio AND immunity. We also
collected references from major reviews cited for polio vaccine
immunogenicity or protection.12–16 Articles on animal and
immunodeﬁcient subjects were excluded.
For data entry, we prioritized reports that had large samples,
measured mucosal immunity, or compared different vaccine
schedules. The analysis is broad, but the literature review is not
systematic or comprehensive. The database is made available for
further work by the community. We excluded studies, or portions
of them, if measurements were quantiﬁably compromised in some
manner or if the data were reported in a form that precluded Monte
Carlo sampling of subjects.
We transcribed data from published articles into an Excel
spreadsheet (Supplementary Material, Additional File 1). We used
MATLAB to analyze data by nonlinear least squares parameter
ﬁtting (Supplementary Material, see Additional File 2 for
codebase). Uncertainties of parameters were measured according
to the method of Balsamo et al.17 To disaggregate mean study
group values to individual subjects, we used Monte Carlo sampling
of the immune state. The immune trajectories were calculated
individually for each sampled subject and ﬁnally aggregated back
to their respective synthetic study groups to compare predicted to
observed outcomes. Supplemental information on methods and
results can be found in the Supplementary Material (Additional
File 3).
Host factors for vaccine failure (enteroviruses, breast-feeding,
and diarrhea) were analyzed by Fisher’s exact test for statistical
signiﬁcance within each study. We calculated the relative efﬁcacy
of OPV as the ratio of seroconversion rates of the risk factor group
to the control group. Relative efﬁcacy was also computed
numerically as the ratio distribution of two beta-distributed
random variables, each with parameters a = (1 + seroconverted
subjects) and b = (1 + nonresponding subjects). The Bayesian
analysis on the set of studies calculated the distribution for relativeTable 2
Per-dose vaccine efﬁcacy parameters
Efﬁcacy OPV 1 OPV 2 OPV 3 IPV 1 
Mean 0.56 0.63 0.43 0.15 
SD 0.23 0.23 0.17 0.09 
N subjects 3193 1818 3439 3062 
References 18–38 19, 20, 23, 24, 26–32,
35–37, 39, 40
18–20, 23, 24, 26–32,
35–37, 39–42
18, 19, 22
32–38, 43
OPV, oral polio vaccine; IPV, inactivated polio vaccine; SD, standard deviation.efﬁcacy conditioned on ratio distribution of each study (as
independent observations).
Throughout this text, neutralizing antibody titer (NAb) refers to
the reciprocal dilution of serum or its geometric mean (GMT) that
neutralizes 100 TCID50 (tissue culture infectious dose) of poliovi-
rus.
2.1. Exclusion criteria
We assessed exclusion criteria individually for each measure-
ment in each study group (Table 1). If only some study arms of a
trial failed the screen, we excluded those while retaining the
others. We excluded measurements reported in a form that
obscured or mixed data and could not be sampled.
3. Results
We used a lower-complexity model of per-dose efﬁcacy to
measure vaccine-induced protection against infection upon
challenge. We measured the efﬁcacy of each serotype of OPV
and IPV as parameters in the model with respect to dose history
and without regard for vaccine formulation. This model obtained a
different mechanistic interpretation of the dataset than the
immunity model. While one model ﬁt better than the other, both
were useful tools signiﬁcantly associated with the data. To capture
more of the features of poliovirus infections, we incorporated
serology data into an immune model and ﬁt it to the challenge
study data.
3.1. Per-dose efﬁcacy model
The per-dose efﬁcacy model was ﬁt to the data to investigate
the value of dose history alone as a predictor of intestinal
immunity, using a low-dimensional model. This model did not
depend on serostatus. Six parameters described the efﬁcacy of OPV
and IPV serotypes 1 to 3 (equation 1). Each serotype was
considered to act independently, even in multivalent formulations.
Fitting the per-dose efﬁcacy model to intestinal immunity data,
we found that dose history signiﬁcantly predicted intestinal
immunity (correlation coefﬁcient 0.43, p = 0.001).
For each serotype s, the probability of infection upon challenge
was the probability that all doses of OPV and IPV failed to protect
the individual. The challenge dose was predominantly trivalent
OPV (tOPV), but studies challenging with monovalent OPV (mOPV)
were also included in the analysis.
pinf;s ¼ ð1  E f ficacyIPV ;sÞdosesIVP ð1  E f ficacyOPV ;sÞdosesOVP (1)
We estimated protection only from the number of doses
received for each vaccine type. This model showed some of the
expected properties of the vaccines, such as the relative efﬁcacies
between serotypes (Table 2 18–51).
The efﬁcacy value of each vaccine and serotype is the per-dose
probability of protection against infection by tOPV challenge. This
model was ﬁt to vaccine challenge studies and does not measure
the efﬁcacy against disease.IPV 2 IPV 3
0.11 0.11
0.10 0.09
2075 2839
–27, 30,
–49
19, 23, 24, 26, 27, 30, 32,
35–37, 39, 43–45, 47, 48, 50
18, 19, 23, 24, 26, 27, 30, 32, 35–37,
39, 41–43, 45, 47, 48, 50, 51
Figure 1. Susceptibility versus number of doses—summary of all studies in the database. Top row are OPV vaccinees, bottom row are IPV vaccinees. Columns left to right are
serotypes 1, 2, and 3. x-axes are number of doses before challenge; y-axes are fraction of subjects shedding virus following OPV challenge. Area of markers is proportional to
the number of subjects.
M.R. Behrend et al. / International Journal of Infectious Diseases 18 (2014) 4–136Limitations included ignoring the titer of OPV formulations, the
antigen content of IPV, non-tOPV challenges, immune effects on
vaccine take of intermediate doses, and the viral interference
between OPV serotypes. Subjects with no doses of vaccine before
challenge were predicted to be fully susceptible by the dose history
model. The dose history model deviated widely from much of the
study data, implying that additional information about the
subject’s immunity was needed.
3.2. Use of an antibody-based model
To improve measurements of vaccine efﬁcacy, we used an
antibody-based model. In looking at the raw data (Figures 1 and 2),
shedding has some dependence on both serum titer and total
vaccine doses, indicating that immunity may be a predictor for
infections.
3.3. Immunity model deﬁnition
The immunity model is composed of several components that
were treated as independent for the sake of simplicity. The model
consists of a set of equations for immunity induction (equation 8),
antibody boosting (equation 4), and susceptibility to infection
(equation 9). Each of these equations is event-driven in describing
how a sequence of antigen exposures leads to a particular
susceptibility. Vaccine immunogenicity parameters were ﬁt and
then included as inputs to ﬁtting infectivity of Sabin poliovirus and
immune resistance to infection. Fitting these processes indepen-Figure 2. Susceptibility versus serum neutralizing antibody titer—summary of all studies
left to right are serotypes 1, 2, and 3. x-axes are the log2 GMT antibody of each study grou
markers is proportional to the number of subjects.dently underestimates OPV sero-response because not all admin-
istered doses produced gut infection. A more advanced model for
the conditional dependence of these multiple processes is in
development.
First, we measured the half-life (lm) of maternal antibody by
linear regression of the log2NAb titer from serology pairs in infants
before exposure to vaccination. Serum titers for all subjects were
adjusted down by the expected passive immunity at their age to
determine active humoral immunity titers.
log2ðNABmðt þ DtÞÞ ¼ log2ðNABmðtÞÞ 
Dt
lm
(2)
Maternally-derived antibodies at birth are within 0.25 log2GMT
of the mother’s serum titer for types 1 and 2, and lower by 0.6
log2GMT for type 3.
52 Therefore, cord blood and serology of the
mother were accepted as equivalent measurements for the
maternal antibody titer in the infant. The half-life of maternal
antibodies is commonly assumed to be 28 or 30 days. An earlier
review concluded 21 days half-life,53 and a longitudinal study of
passive immunity in infants found a half-life of 24 days.52
Regression of the studies in our database gave a half-life of 22 
5 days (Table 3 20,45,52,54,55).
3.4. Immune priming and boosting for each serotype
The immune response to antigen exposure was modeled
separately for priming and boosting. These models were also ﬁt
separately for IPV and OPV. Priming was taken as the active in the database. Top row are OPV vaccinees, bottom row are IPV vaccinees. Columns
p; y-axes are the fraction of subjects shedding virus following OPV challenge. Area of
Figure 3. Model ﬁt for antibody-mediated vaccine efﬁcacy against infection. Both
axes are the fraction of subjects shedding virus upon challenge in each study group.
Studies include OPV, IPV, and mixed vaccine schedules. Red, green, and blue
markers are serotypes 1, 2, and 3, respectively. Correlation coefﬁcient 0.81, p =
0.0005, slope 0.68. Identity line (dashed) represents a perfect model.
Table 3
Passive immunity
Maternal antibody half-life
Mean 22.2
SD 4.7
N subjects 2056
References 20, 45, 52, 54, 55
SD, standard deviation.
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poliovirus. Boosting was measured as a linear relationship
between pre- and post-vaccine log2 serum neutralizing titer. Only
serology pairs surrounding single doses of vaccine were used. Since
OPV is a live vaccine that replicates in the gut, OPV is assumed to
produce a serologic response independent of the inoculum titer if
an infection results from the dose.
As a starting point, we used the following equation:
log2ðNABnþ1Þ ¼ mboostlog2ðNAbnÞ þ bboost (3)
where n is the number of vaccine doses already taken. The
immunogenicity of each vaccine was measured by the parameters
mboost and bboost. A simpliﬁcation inherent to this model is that the
increase in neutralizing antibody titer is a discrete step.
Rearranging the boosting relationship of equation 3 to measure
the magnitude of the boosting, bboost, and the saturation level for
antibody titer, NAbmax, gives equation 4. In a study of adolescents
with mainly memory immunity, the boosting response to tOPV
showed a saturation effect in which the log2 boost ratio declined in
a linear fashion with the pre-dose log2NAb1.
35 We adopted the
same functional form in equation 4, where immunogenicity is
reduced as log2NAb1 approaches the saturation point. This model
has previously been applied to the immunogenicity of other
vaccines.56 Additionally, an immunogenicity variable, Iboost, was
included to account for the antigen content of different IPV
formulations.
The immune boosting is then:
log2NAb2 ¼ log2NAb1 þ bboostIboost 1 
log2NAb1
log2NAbmax
 
(4)
The immunogenicity of IPV depends on its potency. The
seroconversion rate and log2GMT are both proportional to the
logarithm of D-antigen content.57 The immunogenicity of an IPV
dose with regard to its D-antigen content is calculated relative to
the potency of enhanced IPV (eIPV) as:
ImmIPV ¼ logðD Antigendose þ 1ÞlogðD AntigenEIPV þ 1Þ (5)
where
D AntigenEIPV ¼
40; ty pe 1
8; ty pe 2
32; ty pe 3
8<
: (6)
Equations 4–6 are sufﬁcient to describe humoral immune
responses. The susceptibility model will require a measure of
mucosal immunity, for which we made a transformation of IPV
immunogenicity into OPV equivalents. The parameter kMucIPV
speciﬁes a scaling on mucosal immunogenicity of IPV relative to
OPV. kMucIPV is a factor in immunogenicity and does not imply a
linear relationship between the number of IPV and OPV doses. The
immunogenicity factor for boosting in the mucosal immune
compartment is:
Iboost ¼
1;
1;
kMucIPV ImmIPV ;
OPV dose
IPVðhumoralÞ
IPVðmucosalÞ
8<
: (7)The initial response to antigen exposure of either vaccine was
modeled as:
log2NAb1 ¼ Iboostlog2NAbprime (8)
3.5. Acquisition immunity
Acquisition immunity is described by a separate component of
eight parameters that relate immune state to the probability of
infection. The three Sabin strains of poliovirus each have a speciﬁc
infectivity parameter, P0infs. Neutralizing antibody reduces the
probability of infection from the challenge dose. Three more
parameters, ViralIntfs, measure viral interference in multivalent
doses of OPV. A seventh parameter, kMucIPV, measures the mucosal
efﬁcacy of IPV relative to OPV. An eighth parameter, tAb, represents
the time constant for neutralization of the virus dose.
Single strain acquisition (probability of infection conditioned
on absence of viral interference) is taken as a beta-Poisson process
at a distributed rate R, having a probability of 1  exp(R) for a
nonzero number of events.58 The probability of infection by
serotype s with PVDoses quantity of TCID50 poliovirus is:
pinf;s ¼ 1  1 þ
PVDoses
1  POIn f s
 PoIn f s
NAb1;s
ð1þtAbðNAb1;s1Þð1e1=tAb ÞÞ
(9)
Neutralizing antibodies NAb1,s are the result of the immune
priming and boosting equations for all doses before the present
challenge. Where any vaccine schedule of OPV and/or IPV is used,
NAb1,s is the model’s representation of mucosal immunity, which
may be interpreted as the equivalent serum titer that would yield
the same mucosal immunity in an OPV-only-immunized individ-
ual. The probability of infection (equation 10) by each serotype s
from a multivalent exposure is the product of the single strain
probability (equation 9) and non-interference by other Sabin
strains.
pshed;s ¼ pinf;s
Y
i 6¼ s
ð1  pinf;iviral Int f iÞ (10)
Mucosal immunity can be divided into intestinal and pharyn-
geal compartments, each with its own probability of shedding and
degree of transmissibility. The mucosal parameters were ﬁt to fecal
shedding of poliovirus, and thus reﬂect intestinal immunity. The
intestinal immunity to infection was inferred from a combination
of serum neutralizing titer and dose history. For OPV recipients, the
number of doses or the serum neutralizing titer can indicate
Table 4
Infection acquisition parametersa
P0Inf1 P0Inf2 P0Inf3 tAb ViralIntf1 ViralIntf2 ViralIntf3 kMucIPV
Mean 0.161 0.271 0.131 0.038 0.00 0.157 0.331 0.107
SD 0.026 0.074 0.021 0.021 0.19 0.13 0.14 0.034
N subjects 10 286 8030 9812 13 072 4867 5100 5090 12 619
References 18, 20–25, 27,
28, 30, 31, 33,
35–40, 43–46,
48, 49, 60–62
20, 23, 24, 27,
28, 30, 31, 35–37,
39, 43–45, 48,
60, 62
18, 20, 23, 24,
27, 28, 30, 31,
35–37, 39, 41–43,
45, 48, 51, 60–62
18, 20–25, 27,
28, 30, 31, 33,
35–46, 48, 49,
51, 60–62
20, 23, 27, 28,
30, 31, 35, 36,
39, 43, 45,
60–62
20, 23, 27, 28,
30, 31, 35, 36,
39, 43, 45, 48,
60, 62
20, 23, 27, 28,
30, 31, 35, 36,
39, 43, 45, 48,
60–62
20–25, 27, 28,
30, 31, 33, 35–41,
43–46, 48, 49, 51,
60–62
SD, standard deviation; OPV, oral polio vaccine; IPV, inactivated polio vaccine.
a The model calculates the probability of acquiring infection from these parameters, inputs from the individual’s immune state, and conditions of exposure to the challenge
virus. Viral interference is the probability that an infection of this serotype will block infection by any other serotype. IPV immunogenicity is the immune boosting to the
mucosal compartment relative to OPV in log2 antibody.
Figure 4. Model predictions of intestinal susceptibility through a vaccine schedule. Serotypes 1, 2, and 3 are red, green, and blue, respectively. Susceptibility (y-axis) is the
probability of infection upon monovalent OPV challenge. Mixed schedules (C and D) show the number of OPV doses on the x-axis, which are followed by one or two doses of
IPV (not counted on the axis). The IPV-only dose schedule (B) is intended to represent the upper bound on mucosal protection from an IPV-only history, but not the expected
protection for that schedule, as described in the model design purpose. The combination schedules (C and D) are more representative of the minimum or the expected
protection provided by an IPV dose boosting mucosal immunity previously induced by OPV.
M.R. Behrend et al. / International Journal of Infectious Diseases 18 (2014) 4–138intestinal immunity. The number of doses and serum titer in IPV
recipients are both less clearly related to intestinal immunity.59
An immunity-based model (Figure 3) using serum neutralizing
antibody titer in addition to dose history was more predictive of
intestinal immunity (correlation coefﬁcient 0.81) than dose history
alone (correlation coefﬁcient 0.43). Parameters, uncertainties, and
sources are listed in Tables 4 18,20–25,27,28,30,31,33,35–46,48,49,51,60–62
and 520–24,27,28,30,31,35,41–43,46,47,49,54,55,62–72.
3.6. Immunization trajectories
After ﬁtting model parameters to the database, we applied the
corresponding OPV, IPV, and mixed dose schedules to synthetic
individuals using the model to observe their immune states at each
dose. We then ‘challenged’ these synthetic individuals with OPV to
determine the shedding rate predicted by the model (Figure 4).
Model parameters for immune priming/boosting were drawn from
a distribution of their means and variances upon each individual
exposure to a dose.
3.7. Vaccine efﬁcacy
The efﬁcacy of OPV is much lower than expected in developing
countries.73 Many possible reasons for so-called vaccine failurehave been proposed,74 including environmental enteropathy,75
breast-feeding, maternal antibodies,41,76 non-polio enterovirus
coinfections,28,77,78 diarrhea,64,79 and malnutrition. The relation-
ship of malnutrition to the failure of OPV and other vaccines is
uncertain.80 Although the etiology of vaccine failure has yet to be
clearly identiﬁed, per-dose efﬁcacy against disease has been
measured retrospectively in India81,82 and Nigeria.10,83 In India,
OPV immunogenicity77,84 and protection against infection9 have
also been measured. Monovalent OPV is more effective than the
corresponding serotype in the trivalent formulation,10,82 presum-
ably because it circumvents Sabin–Sabin viral interference.
Maternal antibodies are also known to inhibit the immunological
response to IPV.38,85 Administration of IPV later in infancy
improves seroconversion rates.45,86
Among the studies we reviewed, OPV take was signiﬁcantly
reduced by these host factors. Breast-fed infants were 93% as likely
to seroconvert as those who were formula-fed (Table 6
61,76,77,87,88). Studies of diarrhea were often highly uncertain or
showed modest effects in large samples; few study groups had
below 80% relative efﬁcacy (Table 7 64,76,88,89). Among all studies
observing diarrhea as a risk factor, seroconversion was 94% relative
to controls. Non-polio enterovirus coinfections had the largest
effect, with 79% vaccine efﬁcacy relative to uninfected controls
(Table 8 28,62,77,87,88,90).
Table 6
Breast-feedinga
Reference Breast-fed/artiﬁcial
(conv/N)/(conv/N)
Relative efﬁcacy Statistical power p-Value Author’s conclusions
87 I (33/59)/(13/28) 120% 51% 0.49 Not responsible
88 (86/99)/(8/11) 119% 53% 0.2 Not signiﬁcant
76
Brazil
I (462/534)/(35/39)
II (488/534)/(38/39)
III (324/534)/(34/39)
96%
94%
70%
85%
89%
83%
0.81
0.36
0.001
Signiﬁcant for type 3
77 I (21/42)/(24/32)
II (31/44)/(28/33)
III (18/48)/(14/33)
67%
83%
88%
67%
75%
49%
0.03
0.18
0.82
Only type 1 is affected by feeding
61 I (39/57)/(21/23) 75% 75% 0.04 Marked difference
Total Bayesian inference
95% CI
93%
90–97%
0.001
95% CI, 95% conﬁdence interval.
a Relative efﬁcacy is the unbiased estimate given by the seroconversion rate (converters/N subjects) of breast-fed children divided by the seroconversion rate for formula-
fed. Statistical power is given for the lower bound of the relative seroconversion rate signiﬁcantly different from unity at the sample size (two-tailed Fisher’s exact test). p-
Value is by two-tailed Fisher’s exact test, except for Bayesian inference where the p-value is the integration of the probability density for effect sizes larger than that observed.
Table 5
Vaccine immunogenicity parametersa
OPVprime IPVprime OPVboost OPV
maxLog2NAb
IPVboost IPV
maxLog2NAb
Mean
1)
2)
3)
5.73
6.64
5.49
3.41
3.97
3.75
5.03
6.26
3.09
11.1
11.2
15.3
4.94
5.85
6.08
12.9
15.5
15.2
SD
1)
2)
3)
2.5
2.5
2.5
0.3
1.0
0.8
0.6
1.4
0.3
1.5
0.53
3.7
0.5
0.9
0.6
1.0
2.9
4.0
N subjects
1)
2)
3)
2686
2395
2395
486
486
486
5077
3739
3738
5077
3739
3642
1899
1900
1885
1899
1900
1885
References 20–22, 28,
41, 55, 62–66
47, 54, 63, 67 20–24, 27, 28, 30, 31, 35, 42,
43, 46, 47, 49, 55, 63, 68–70
20–24, 27, 28, 30, 31, 35, 42,
43, 46, 47, 49, 55, 63, 68–70
30, 42, 43, 47,
54, 63, 67, 70–72
30, 42, 43, 47, 54,
63, 67, 70–72
OPV, oral polio vaccine; IPV, inactivated polio vaccine; SD, standard deviation.
a The immunogenicity of OPV and IPV were parameterized as boosting magnitude and saturation titer in log2NAb. Upon ﬁrst successful vaccine take, individuals are
assigned a priming immunity from the normal distribution of priming titer. Subsequent exposures use the boosting parameters. Immunogenicity is reduced as the immune
state approaches the maxLog2NAb. Rows list values for serotypes 1, 2, and 3.
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Observations of shedding duration from wild poliovirus (WPV)
cases can be used to estimate the maximum duration of shedding
for WPV infections. WPV infections last longer than their Sabin
counterparts.14 Poliovirus duration of shedding has been previ-
ously reviewed for cross-sectional and longitudinal studies for
both vaccine and wild virus infections.14
3.9. IPV immunogenicity and efﬁcacy against infection
Although it is generally recognized that IPV reduces oropha-
ryngeal shedding, its effects on fecal shedding are regarded as
uncertain.16,91,92 We measured the protective effect of IPV
through an immunogenicity parameter that represents the
impact of IPV on intestinal immunity relative to OPV.One trial
in an environment free of live virus did not ﬁnd protection from
infection by IPV alone.45 Another meta-analysis found the relative
odds of infection to be 0.81 after an IPV schedule versus
unvaccinated.11 Observations of IPV-induced mucosal immunity
have been called into question, contending that some subjects in
IPV study arms had acquired live poliovirus infections outside of
the study design.93 We excluded studies with measurable livevirus contamination of the study group (Table 1). Limitations
common to our analysis and that of Hird and Grassly are that the
immunity to challenge may reﬂect (1) some amount of passive
vaccination from community contacts, and (2) relative IPV
mucosal immunogenicity without a distinction between induc-
tion and boosting. Therefore, the IPV mucosal immunogenicity
kMucIPV we report may be best interpreted as an upper bound for
induction and as the expected immunogenicity in the context of
boosting.
According to our model (in the absence of host factors),
combined schedules of tOPV followed by one or two doses of IPV
provided modest reductions in susceptibility to infection. If
speciﬁc OPV failure rates for developing countries73 are consid-
ered, we expect the mucosal immunity effectively induced by OPV
schedules to be diminished; this would reduce the difference
compared with IPV.
IPV and OPV have a synergistic effect on immunity in sequential
combination vaccine schedules.94 Children administered tOPV
responded to more serotypes if they had previously received one or
two doses of Salk IPV than children who had no prior vaccination.95
Conversely, a booster dose of IPV induces a strong memory
response in mucosal IgA antibodies for individuals previously
vaccinated with OPV.93
Table 7
Diarrheaa
Reference Diarrhea/none
(conv/N)/(conv/N)
Relative efﬁcacy Statistical power p-Value Author’s conclusions
89
4th dose
I (9/19)/(78/165)
II (4/9)/(34/83)
III (5/33)/(69/301)
100%
109%
66%
66%
58%
48%
1
1
0.38
89
3rd dose
I (11/22)/(130/303)
II (5/14)/(61/144)
III (6/29)/(104/415)
117%
84%
83%
70%
56%
53%
0.51
0.78
0.82
More signiﬁcant cumulatively
89
2nd dose
I (11/32)/(196/490)
II (7/22)/(162/305)
III (4/36)/(186/598)
86%
60%
36%
65%
59%
43%
0.58
0.08
0.01
Signiﬁcant failure for types 2 and 3
76
Brazil
I (72/84)/(559/644)
II (73/84)/(601/644)
III (45/84)/(423/644)
99%
93%
82%
92%
93%
82%
0.73
0.04
0.04
Signiﬁcant for type 3
76
Gambia
I (151/177)/(420/502)
II (164/177)/(484/502)
III (113/177)/(377/502)
102%
96%
85%
94%
96%
89%
0.64
0.06
0.005
Signiﬁcant for type 3
88 (43/51)/(55/63) 97% 87% 0.79 Insigniﬁcant
64
3rd dose
I (68/99)/(150/213)
II (77/100)/(178/210)
III (67/100)/(159/214)
98%
91%
90%
87%
89%
85%
0.79
0.11
0.18
Lower trend for types 2 and 3
64
1st dose
I (33/99)/(71/210)
II (40/98)/(116/209)
III (27/99)/(88/212)
99%
74%
66%
74%
76%
70%
1
0.02
0.02
Signiﬁcant for types 2 and 3
Total Bayesian inference
95% CI
94%
91–97%
0.0003
95% CI, 95% conﬁdence interval.
a Relative efﬁcacy is the unbiased estimate given by the seroconversion rate (converters/N subjects) of diarrhea subjects divided by the seroconversion rate for controls.
Statistical power is given for the lower bound of the relative seroconversion rate signiﬁcantly different from unity at the sample size (two-tailed Fisher’s exact test). p-Value is
by two-tailed Fisher’s exact test, except for Bayesian inference where the p-value is the integration of the probability density for effect sizes larger than that observed.
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fecal and pharyngeal shedding durations in subjects naturally
acquiring WPV infection.96 Two doses of IPV signiﬁcantly reduce
the capacity for infected individuals to transmit the virus to others
by decreasing infection duration and shedding titer.26 Some data
indicate that the excretion index (total virus shed during infection)
in infected children who received IPV is 5% compared to infected
unvaccinated individuals.97
After the global incidence of poliomyelitis has been reduced by
about 99%, largely by the use of OPV, there will be an increasing
role for IPV in the eradication of the last 1%.1 IPV has been usedTable 8
Enterovirus infectionsa
Reference Enterovirus/none
(conv/N)/(conv/N)
Relative efﬁcacya Statistical
90b I (19/86)/(6/42)
II (50/89)/(20/37)
III (32/107)/(13/46)
155%
104%
106%
16%
64%
50%
28 dose 2 I (61/146)/(17/23) 57% 69% 
77 I (9/17)/(28/45)
II (11/16)/(41/51)
III (5/16)/(20/55)
85%
86%
86%
64%
75%
51%
62
A summer
I (5/6)/(19/20)
II (6/6)/(20/20)
III (5/6)/(20/20)
88%
100%
83%
53%
67%
67%
87 I (17/38)/(29/49) 76% 66% 
62
B summer
I (6/12)/(16/17)
II (10/12)/(17/17)
III (8/12)/(16/17)
53%
83%
71%
57%
67%
67%
88 I and III (0/8)/(33/41) 0% 47% 
Total Bayesian inference
95% CI
79%
70–88%
95% CI, 95% conﬁdence interval.
a Relative efﬁcacy is the unbiased estimate given by the seroconversion rate (converter
controls.
b Measurement is shedding upon challenge instead of seroconversion.exclusively or in combination with OPV in many countries.91,98
Experiences of limited success with OPV have led to questions on
vaccine choice well before the eradication of wild polioviruses.99
Considerations for OPV cessation100,101 and the polio end-
game15,94,102 have prompted investigations into low-cost methods
for widespread IPV administration.
Phasing out vaccine strain polioviruses will likely make use of
IPV in some manner to suppress circulation of VDPVs103 following
the last administration of live virus. In polio-free countries, or
those experiencing OPV failure, IPV may be desirable in combina-
tion for immune-boosting with OPV or as a replacement.104 The power p-Value Author’s conclusions
0.35
0.85
1
Not signiﬁcant
0.006 Signiﬁcant
0.57
0.33
0.77
No effect
0.41
1
0.23
Deﬁnitely lower
0.20 Adverse effect
0.01
0.16
0.13
Deﬁnitely lower
3e5 Signiﬁcant
2e6
s/N subjects) of enterovirus-infected children divided by the seroconversion rate for
M.R. Behrend et al. / International Journal of Infectious Diseases 18 (2014) 4–13 11extent to which IPV can reduce VDPV risks through induction or
boosting of mucosal immunity is still uncertain, as is the maximum
reproductive number for which IPV could prevent transmission.
3.10. Viral interference
The efﬁcacy of OPV is also suspected to be affected by
coinfection with non-polio enteroviruses.78,87,105 Although few
individual studies found signiﬁcant associations between vaccine
failure and excretion rates of non-polio enteroviruses, we found
the overall effect of these studies to be signiﬁcant, with a relative
efﬁcacy of 79% (Table 8) in the presence of coinfection.
4. Conclusions
Our model contributes to the increased quantitative analysis of
data recommended by the Independent Monitoring Board of the
Global Polio Eradication Initiative for decision-making.2 Options
for OPV cessation have unknown risks for the emergence of
circulating VDPV (cVDPV). Additionally, the possibility remains
that cVDPV or WPV could be reintroduced to a population of
subsequently fewer immunized individuals following cessation of
any Sabin serotype.
The degree of protection IPV might provide in bridging the
immunitygap from OPV cessation to Sabin containmentcertiﬁcation
is unknown. We determined that the impact of IPV to mucosal
boosting is11%ofthat for OPV. IPV-immunizedpopulationswillhave
lowermucosalimmunity,butimmunitymustbeevaluatedinspeciﬁc
populations to determine if IPV is adequate to prevent transmission.
We presented models for per-dose vaccine efﬁcacy and antibody-
mediated protection from infection with parameters derived from a
broad survey of the literature. Both models were signiﬁcantly
correlated with the data. Using the parameter values derived from
the data, the immune model produced immunity trajectories similar
to those observed in response to the dose schedules of vaccine trials.
Vaccine failure was not clearly associated with non-polio
enteroviruses or breast-feeding in individual studies. When the
ensemble of studies was analyzed, breast-feeding, enterovirus
infections, and diarrhea were all signiﬁcantly associated with
vaccine failure. Seroconversion was 79% with enterovirus coinfec-
tion relative to controls. Relative vaccine take was 93% for breast-
feeding and 94% for diarrhea versus controls. Further investigation
will be needed to fully explain the higher rates of OPV failure
described by Patriarca et al.73
The polio eradication program has steadily increased the
number of SIAs in endemic countries. This is partly due to vaccine
failure10,81,98 and partly to inadequate vaccine coverage by the
campaigns.2,106 Endemic countries currently need to carry out
house-to-house mass vaccination campaigns almost month-
ly;4,81,106 this warrants further investigation into the mechanisms
of vaccine failure and implementation of practices that deliver
vaccine to consistently missed children.
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